SuRo Capital Corp. to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024 NEW YORK, May 02, 2024 (GLOBE NEWSWIRE) -- (“SuRo Capital”) (Nasdaq: ) today announced that it will report its financial results for the quarter ended March 31, 2024 after the close of the U.S. market on Wednesday, May 8, 2024. Management will hold a conference call and webcast for investors at 2:00 p.m. PT (5:00 p.m. ET). The conference call access number for U.S. participants is 866-580-3963, and the conference call access number for participants outside the U.S. is . The conference ID number ...
Arvinas to Present at Upcoming Investor Conferences NEW HAVEN, Conn., May 02, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in two upcoming investor conferences: BofA Securities 2024 Healthcare Conference on Tuesday, May 14 at 3:00 p.m. PT in Las Vegas. Noah Berkowitz, M.D., Ph.D., Chief Medical Officer, and Randy Teel, Ph.D., Chief Business Officer, will participate in a fireside chat. A live audio webcast of the presen...
Compass Diversified Reports First Quarter 2024 Financial Results WESTPORT, Conn., May 01, 2024 (GLOBE NEWSWIRE) -- Compass Diversified (NYSE: CODI) (“CODI” or the “Company”), an owner of leading middle market businesses, announced today its consolidated operating results for the three months ended March 31, 2024. “We started 2024 on a strong note especially when you look at the performance of our Branded Consumer businesses, which only underscores the effectiveness of our well-defined, strategic pivot to own and manage companies at the forefront of innovation and disruptive growth,” said...
Compass Diversified Announces Sale of Crosman Air Gun Business WESTPORT, Conn., April 30, 2024 (GLOBE NEWSWIRE) -- Compass Diversified (NYSE: CODI) (“CODI” or the “Company”), an owner of leading middle market businesses, is announcing the simultaneous entry into a definitive agreement (the “Agreement”) and completion of its sale of Crosman Corporation (“Crosman”), the air gun division of its Velocity Outdoor, Inc. subsidiary, to Daisy Manufacturing Company (“Daisy”). Crosman is a leading designer, manufacturer and marketer of air guns, accessories and related consumables sold under the C...
Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma $15 million CIRM Grant Supports the Ongoing Phase 1 TRAVERSE Trial Evaluating ALLO-316 in Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)ALLO-316 Illustrates Proof-of-Concept in RCC and the Potential of Dagger® Technology to Optimize CAR T Cell Expansion and Persistence SOUTH SAN FRANCISCO, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology comp...
Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer NEW HAVEN, Conn., April 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the appointment of Randy Teel, Ph.D., to the newly created role of Chief Business Officer. Dr. Teel currently serves as Arvinas’ interim Chief Financial Officer and Treasurer, and in his new role, he will remain a member of the Executive Committee reporting to Chairperson, President and Chief Executive Officer, John Houston,...
Compass Diversified-Backed The Honey Pot Co. Strengthens Its Board With The Appointment of Three New Directors Three Accomplished Women Bring Deep Expertise Rooted in Innovation to Further the Brand’s Growth Strategy WESTPORT, Conn., April 18, 2024 (GLOBE NEWSWIRE) -- The Honey Pot Company, LLC (“The Honey Pot Co.” or “the Company”), a leading “better-for-you” feminine care brand, together with its partner, Compass Diversified (NYSE: CODI) (“CODI”), proudly announces the appointment of three new directors - Janis Smith-Gomez, former executive of Johnson & Johnson; Dr. Maria Sophocles, a...
Compass Diversified Announces First Quarter 2024 Earnings and Conference Call Information WESTPORT, Conn., April 17, 2024 (GLOBE NEWSWIRE) -- Compass Diversified (NYSE: CODI) (“CODI” or the “Company”), an owner of leading middle market businesses, announced today that it plans to release financial results for the first quarter ended March 31, 2024, on Wednesday, May 1, 2024, after the close of market trading. The Company has scheduled a conference call to discuss the results on Wednesday, May 1, 2024, at 5:00 p.m. ET. In conjunction with reporting first quarter 2024 results, CODI will ho...
SuRo Capital Corp. First Quarter 2024 Preliminary Investment Portfolio Update Net Asset Value Anticipated to be $6.90 to $7.40 Per Share NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- (“SuRo Capital”, the “Company”, “we”, “us”, and “our”) (Nasdaq: ) today provided the following preliminary update on its investment portfolio for the first quarter ended March 31, 2024. “We remain incredibly enthusiastic about both our investment pipeline and our current portfolio as the IPO market strengthens and new opportunities at compelling valuations continue to come to light. We are now executing on...
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer – Arvinas to receive a $150 million upfront payment for the license of ARV-766 and the sale of Arvinas’ preclinical AR-V7 program, with the potential under the License Agreement for up to $1.01 billion in development, regulatory, and commercial milestones, as well as tiered royalties – – Novartis to be responsible for worldwide clinical development and commerciali...
Allogene Therapeutics Announces Q2 Investor Conference Participation SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in four investor conferences in the second quarter of 2024. Canaccord Genuity Horizons in Oncology Virtual ConferenceMonday, April 15, 202412:00pm PT/3:00pm ET JPM Securities Life Sciences Conference Tuesday, May 14, 20246:00am PT/9...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.